Yissum - Research Development Company of the Hebrew University

a Novel pre-treatment for the Prevention of Allergic reactions to medicines using a drug-free Carriers

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Treatment with a placebo, drug-free carrier, prior to administration of particulate medicines to prevent allergic reactions to the medicines

Formulation
Project ID : 6-2008-2098

Description of the technology

Background

  • Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles cause hypersensitivity reactions in up to 45% of patients,

which appear to be initiated by the complement system (C) of the immune system.
  • Liposomes, Micelles,and other particulate drug carriers which do not carry C inhibitors on their surfaces will activate these hypersensitive reactions.
  • Our Innovation

    a Novel treatment to prevent Allergic reactions to medicines by using a placebo drug-free Carrier, prior to the administration of particulate medicines

    Applications for use:

    Preventing an allergic reactions to medicines

    Key Features

    • Technology specifically inhibits PCM-triggered C3a/C5a receptor-mediated complement activation-related pseudoallergy (CARPA) reactions
    • Toxicology tests for this technology are very simple

    The Opportunity

    Opportunity to incorporate new technology with minimal regulatory process

    Researcher Informationbiochemistry.huji.ac.il/faculty_barenholz.asp,research.ekmd.huji.ac.il/researchers.asp?id=166,nanoscience.huji.ac.il/researchers/barenholz.htm

    Project manager

    Keren-Or Amar
    VP, Business Development, Healthcare

    Project researchers

    Yechezkel Barenholz
    HUJI, School of Medicine - IMRIC
    Biochemistry and Molecular Biology

    Related keywords

    • Medicine, Human Health
    • Biology / Biotechnology
    • Genome Research
    • Micro- and Nanotechnology related to Biological sciences
    • Recombinant DNA
    • Monoclonal Antibodies and Hybridomas
    • Gene Splicing and Manufacturing Equipment
    • Other Genetic Engineering
    • Molecular design Market
    • Microbiology Market
    • Micro- and Nanotechnology related to Biological sciences
    • Biochemistry / Biophysics Market
    • Toxicology Market
    • In vitro Testing, Trials Market
    • Stem cells and biobanks
    • Cellular and Molecular Biology Market
    • Population genetics Market
    • Gene Expression, Proteom Research Market
    • Bioinformatics Market
    • Enzymology/Protein Engineering/Fermentation
    • Genetic Engineering Market
    • Clinical Medicine
    • Anatomy, Pathology, Immunology, Physiology
    • Agro and Marine biotech
    • Other Medical/Health Related
    • Therapeutic
    • Diagnostic
    • Life Science & Biotechnology
    • immunology

    About Yissum - Research Development Company of the Hebrew University

    Technology Transfer Office from Israel

    Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

    Send your request

    By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

    Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.